A pilot study about culturing laryngeal tumor tissue organoids to facilitate new treatment strategies for laryngeal cancer in the future

A pilot study about culturing laryngeal tumor tissue organoids to facilitate new treatment strategies for laryngeal cancer in the future - Organoids model in laryngeal cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON55128

Enrollment

Registered

2021-04-23

Start date

2022-10-10

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laryngeal cancer Laryngeal carcinoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - proven carcinoma of the larynx. - > 18 yrs of age - planned routine biopsy or planned surgical resection as part of standard diagnostic work-up or treatment - expected tumor volume > 2 cm3 - informed consent

Exclusion criteria

Exclusion criteria: - no squamous cell carcinoma after definitive histolopathological analysis

Design outcomes

Primary

Measure	Time frame
In ex vivo LC organoids: viable and proliferating organoids after at least 2 and 6 weeks in 50% of the samples. To assess viability and to confirm the origin of each tumor specimen, the specimen will be evaluated by analysis of non-necrotic tumor tissue in hematoxylin-eosin stained tissue sections and by determining proliferation rate on day 0, week 2 and week 6, using organoid formation and growth rate and by using whole genome DNA sequencing (~30x coverage (~100 Gb)).	—

Measure

Time frame

In ex vivo LC organoids: viable and proliferating organoids after at least 2 and 6 weeks in 50% of the samples. To assess viability and to confirm the origin of each tumor specimen, the specimen will be evaluated by analysis of non-necrotic tumor tissue in hematoxylin-eosin stained tissue sections and by determining proliferation rate on day 0, week 2 and week 6, using organoid formation and growth rate and by using whole genome DNA sequencing (~30x coverage (~100 Gb)).

—

Secondary

Measure	Time frame
We will analyse differences in solidity of ex vivo LC organoids between primary and recurrent LC tissue by using a Chi-square test with SPSS.	—

Countries

Netherlands

Outcome results